Verrica Pharmaceuticals to Attend Jefferies Global Healthcare Conference in New York

WEST CHESTER, Pa., May 30, 2024 – Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a company focused on developing treatments for dermatological conditions, has announced that its President and CEO, Ted White, will be speaking at the Jefferies Global Healthcare Conference. The event is scheduled to take place in New York City on June 6, 2024.

The Jefferies Global Healthcare Conference is a significant event in the healthcare industry, bringing together leading companies and experts to discuss advancements and strategies within the sector. Mr. White’s participation will feature a fireside chat, providing insights into Verrica’s current and future endeavors.

Event Details:
- Date: Thursday, June 6, 2024
- Time: 3:30 pm ET
- Location: New York, NY

A live webcast of the talk will be accessible through the Verrica Pharmaceuticals website in the Investors/Presentations & Events section. This webcast will also be available for replay for 90 days after the event, ensuring that interested parties who cannot attend live can still benefit from the information shared.

About Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals specializes in creating medical treatments for skin diseases. One of their flagship products, YCANTH (cantharidin), holds the distinction of being the first FDA-approved treatment for molluscum contagiosum available for both adults and children aged two and older. Molluscum contagiosum is a viral skin infection that is particularly prevalent among children, affecting around 6 million people in the United States.

In addition to YCANTH, Verrica is advancing the development of VP-102, aimed at treating common and external genital warts, addressing significant unmet needs in dermatology. Another key product in Verrica’s pipeline is VP-103, a second cantharidin-based treatment targeting plantar warts.

Beyond its internal developments, Verrica has also entered into a global licensing agreement with Lytix Biopharma AS. This collaboration focuses on the development and commercialization of VP-315 (formerly LTX-315 and VP-LTX-315) for treating non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma.

This strategic participation in the Jefferies Global Healthcare Conference highlights Verrica Pharmaceuticals' commitment to engaging with the broader healthcare community and sharing their advancements in dermatological therapeutics.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!